Interleukin-18 is a potent cytokine expressed early in the
Introduction
IL-18, originally cloned from mice suffering fulminant hepatitis induced by the administration of Propionibacterium acnes and LPS. It induces high level of IFN-␥, GM-CSF, IL-1 and IL-13 secretion by natural killer (NK), T cells, B cells and, with IL-12, monocytes.
1,2 IL-18 also plays an important role in T cell proliferation, 1 CTL activation 3 and enhancement of NK cell cytolytic activity mediated primarily via FasL-Fas mechanism with perforin mediating a less important role. 2, 4, 5 Recent studies have shown that IL-18 also induces Th2 cytokines, including IL-13, IL-1, IL-10 and in synergy with IL-2, but not with IL-12.
6-8 Systemic administration of recombinant (r) IL-18 is associated with significant in vivo antitumor effects which appear to be mediated by NK cells as the primary effector cells. 9 11 We have also shown that this antitumor effect is completely abrogated by the depletion of asialo GM-1-positive cells. 11 Potent and tumor-specific CTL can be induced by DC fed with tumor cells destroyed by NK cells in a coculture system containing rIL-18. 12 We analyzed the mechanism of the antitumor effect associated with i.t. injection of Ad.PTH.IL-18 using gld (FasL deficient) mice focusing on CTL induction. Furthermore, we have developed a novel strategy using i.t. injection of both Ad.PTH.IL-18 and DC. This strategy was associated with potent antitumor effects not only on the treated tumor lesion, but also on the untreated tumors on the contralateral flank. These results indicate that i.t. injection of both Ad.PTH.AdIL-18 and DC induces potent and specific antitumor immunity through enhancement of NK activity. 11 significant antitumor effects were observed in mice treated with Ad.PTH.IL-18 when compared with mice injected with a control adenoviral vector, Ad.EGFP (P = 0.0025), or HBSS (P = 0.0033) ( Figure 1B) . In contrast, when gld mice were treated with Ad.PTH.IL-18, no significant antitumor effects were observed (P = 0.508 against mice treated with Ad.EGFP, P = 0.273 against mice treated with HBSS) ( Figure 1B) Figure 1C ). In gld mice, i.t. injection of Ad.PTH.IL-18 did not enhance tumor specific IFN-␥ responses (137 ± 11 pg/ml) or in vitro cytotoxic activity ( Figure 1C) responses were observed in MC38, another syngeneic mouse tumor system (Figure 3 ).
Results

Intratumoral injection of the IL
Cellular immune response associated with the treatment with Ad.PTH.IL-18 and DC is specific for the treated sarcoma, and MHC class-I-restricted
To examine the nature of the antitumor effects, lymphoid cells were collected from lymph nodes and spleens of the treated animals. The most potent cytolytic activity of those effector cells was generated against MCA205 cells when the animals were treated with Ad.PTH.IL-18 and DC. Treatment with DC alone, DC plus control vector, or Ad.IL-18 alone showed significant, but modest increase of cytolysis (Figure 2c) . To analyze the specificity of effector cells generated from the lymphoid cells of the animals treated with Ad.PTH.IL-18 and DC, cytolytic activity of effector cells were assayed against four different syngeneic tumor cell lines (MCA205, MC38, EL-4, B16), and YAC-1 (a NK sensitive cell line). Cytotoxicity of the effector cells was significantly enhanced only against MCA205 cells, and not other cell lines (P Ͻ 0.01 for all) ( Figure  4a ). When the effector cells were incubated with anti MHC class I antibody, the cytolytic activity was significantly inhibited (Figure 4b ). To confirm the character of effector cells, we injected anti-MHC class I antibody in vivo before treatment with Ad.PTH.IL-18 and DC. The cytolytic activity of LN cells of the treated mice was significantly inhibited when treated with anti-H2k b mAb (24%) compared with the control antibody (52%) at the E:T ratios of 50. These results support the notion that cytolytic activity of the effector cells in this system is MCA205-specific and MHC class I-restricted.
Coinjection of Ad.PTH.IL-18 and DC can be effective against an adenocarcinoma
We analyzed the efficiency of this i.t. injection of both Ad.PTH.IL-18 and DC on the MC38 adenocarcinoma tumor cell line. As shown in Figure 3a , significant antitumor effect was observed in the injected tumor with i.t. coinjection of Ad.PTH.IL-18 and DC. The effects were superior to that of tumors treated with DC alone (P Ͻ 0.001), DC plus control vector (P Ͻ 0.001), or Ad.PTH.IL-18 alone (P Ͻ 0.01). The antitumor effect was also observed against non-injected distant tumor on the contralateral flank of treated animals ( Figure 3b ). These results support the approach of using i.t. coinjection using Ad.PTH.IL-18 and DC. This can be an effective therapy even against weakly immunogenic tumors including the MC38 adenocarcinoma.
Discussion
Based on our previous study demonstrating potent in vitro CTL induction using IL-18 protein, NK cells, DC and live tumor cells, 12 we hypothesized that i.t. co-injection 12 Eliminating any one of these components reduced the generation of these tumor-specific T cell responses. Taken together, we hypothesized that innate immune response mediated by the FasL-Fas system on NK cells is a key mediator of potent CTLs by IL-18 in this coculture system. Consistent with the results of systemic administration of IL-18 protein study, the in vivo antitumor effect of Ad.PTH.IL-18 was significantly inhibited in gld mice compared with that of otherwise immunocompetent mice in the current study ( Figure 1) . Furthermore, induction of CTL was significantly inhibited in gld mice treated with Ad.PTH.IL-18. In our previous study using an in vitro coculture, 12 potent CTLs could not be induced following direct contact of NK cells with T cells, DC, and live tumor cells were inhibited even in the presence of IL-18 protein in the same coculture system. 12 Taken together, these results suggest that NK activity mediated through Fas-FasL interactions requires direct effector-target contact and plays an important role for the generation of potent CTLs specific to the tumor both in vitro and in vivo.
DC appear to play an important role as primary antigen-presenting cells to initiate and maintain T cell responses acquiring tumor cells destroyed following locally expressed IL-18 activation of NK cell. 5, 9, 12 We hypothesized that immature DC would acquire destroyed tumor cells, mature with alternation in release cytokine and express chemokine receptor, 13 and migrate into draining lymph nodes. DCs in the T cell area of the regional lymph nodes could then activate and educate naive T cells to become tumor-specific CTLs. [14] [15] [16] [17] This hypothesis is also consistent with our previous report of co-culture systems using NK cells, DCs, T cells, live tumor cells and IL-18 protein in vitro. 12 To examine the involvement of endogeneous IL-12 in potent antitumor effects mediated by Ad.PTH.IL-18 and DC, we used DCs cultured from IL-12 gene deficient (IL-12 GKO) mice. Coinjection of Ad.PTH.IL-18 and DC from IL-12 GKO mice was associated with significantly fewer antitumor effects when compared with that of the treatment with DCs from immunocompetent animals. The cytolytic activity was lower (17%) with the LN cells harvested from IL-12 GKO mice treated with DC-Ad.PTH.IL-18 combination than that (30%) with the LN cells harvested from immuno-competent mice so treated. This result suggests that the antitumor effect induced with coinjection of Ad.PTH.IL-18 and DC plays important role for inducing adoptive immune response with endogenous IL-12. This observation is consistent with the reported synergistic effect between IL-18 and IL-12 as reported in multiple systems including fungus infection, 18 Toxoplasma gondii infection, 19 angiogenesis inhibition in murine tumor models, 20 and effective activation of CD8 positive T cells. 3 Recently, multiple interactions between NKs and DCs have been reported. Activated NK cells kill immature DCs, 21, 22 but induce maturation of DCs. 23 Direct contact of NK cells induces either activation or inhibition of DC functions. 24, 25 In our setting locally expressed IL-18 could activate NK cells, which might kill immature DCs. Thus, therapeutic efficiency of the DC injection could be somewhat, but not totally, hampered by this phenomenon.
To investigate the nature of antitumor immune response obtained in this system, we tested the specificity and MHC class-I restriction of effector cells against tumor cells. Cytolytic activity of CTLs cultured from splenocytes of treated animals were significantly elevated against inoculated tumor when compared with those against three other syngeneic and NK-sensitive tumor cells. Thus, antitumor effect against the tumor at distant site appears to be mediated by tumor-specific effector cells generated by co-injection of both Ad.PTH.IL-18 and DC. Mice that had completely rejected an initial tumor challenge subsequently received 1 × 10 6 tumor cells. All of the mice so treated completely rejected the tumor (data not shown). The cytolytic activity in vitro was significantly abrogated using anti-MHC class I antibody. These results indicate that coinjection of Ad.PTH.IL-18 and DC generate tumorspecific cytolytic activity that was MHC class I-restricted, and extend our previous observation with IL-12 transfection.
Other groups have also reported the promising effects of direct injection of IL-18 vectors 9, 26, 27 or administration of DCs genetically engineered to express IL-18 28 in the tumor or hepatic fibrosis models. Intratumoral injection of both Ad.PTH.IL-18 and DC induces potent and specific immunity consistent with the results observed in the in vitro coculture system. IL-18 and DC thus play critical inductive and interactive role in promoting tumor-specific immunity. This approach might indeed be applicable to patients with cancer.
Materials and methods
Adenoviral vectors
Construction of the IL-18 vector was described previously. 11 In brief, the fragment encoding the prepro leader peptide of human parathyroid hormone 29 was fused to the sequence encoding mature IL-18 cDNA, termed PTH.IL-18. The PTH.IL-18 fragment was inserted into a shuttle plasmid 30 termed pAdlox to make an E1-and E3-deleted recombinant adenoviral vector designated Adlox.PTH.IL-18 ( Figure 1A) . A recombinant adenoviral vector encoding PTH.IL-18 was generated through Cre-lox recombination as previously described, 30 termed Ad.PTH.IL-18. All of the necessary materials for construction Ad.PTH.IL-18 were generous gifts from Dr Stephen Hardy. An adenoviral vector expressing EGFP (Ad.EGFP) was created in the same manner by subcloning the respective fragments obtained from pEGFP-N1 (Clontech, Palo Alto, CA, USA) 31 ( Figure 1A) . Expression of mIL-18 was determined in an mIL-18 ELISA using MCA205 sarcoma infected at different multiplicities of infection (MOI) with Ad.PTH.IL-18 ( Figure 1A) , and biological activity was confirmed as described previously.
11
Recombinant cytokines Murine rIL-18 was supplied by Hayashibara Biochemical Laboratories (Okayama, Japan). Murine rIL-4 and murine GM-CSF were supplied by Dr Satwant Narula, ScheringPlough Research Institute, Kenilworth, NJ, USA. rhIL-2 was kindly provided by Chiron, Emeryville, CA, USA.
Tumor cell lines, dendritic cells and animal experiments
MCA205, a methylcholanthrene-induced murine fibrosarcoma cell line, and MC38, murine adenocarcinoma, were a generous gift from Dr SA Rosenberg, National Cancer Institute, Bethesda, MD, USA. YAC-1 was a generous gift of W Chambers (University of Pittsburgh, Pittsburgh, PA, USA). These cell lines were maintained in RPMI1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 mg/ml streptomycin, 100 IU/ml penicillin, and 5 × 10 Ϫ5 M 2-ME (all from Life Technologies, Grand Island, NY, USA), referred to henceforth as complete medium (CM). 32 Bone marrowderived dendritic cells (BM-DCs) cultured with GM-CSF and IL-4 for 6 days were prepared as previously described. 32 In brief, murine bone marrow cells were harvested from the femur and tibia of dead mice. Contaminating erythrocytes were lysed with 0.83 M NH4Cl buffer and lymphocytes were depleted with cocktail of antibodies (RA3-3A1/6.1, anti-B220; 2.43, anti-Lyt 2; GK1.5; anti-L3T4; all from American Type Culture Collection, Rockville, MD, USA) and rabbit complement (Accurate Chemical and Scientific, Westbury, NY, USA) on day 0. These cells were cultured overnight in CM to remove the adherent macrophages, and non-adherent cells were placed in fresh CM containing rmGM-CSF (1000 U/ml) and rmIL-4 (1000 U/ml) (DC media) on day 1. This cell population, cultured for 6 days in this condition, predominantly consisted of cells with the characteristic morphology and surface phenotype compatible with constitutively immature DCs. Phenotypic analysis with flow cytometry was performed on all preparations used in this study as described below to ensure the quality of the cell preparation used. Wild-type (WT) C57BL/6 mice were purchased from Taconic Farms (Germantown, NY, USA). The gld (FasL-deficient) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). These animals were maintained in the animal facility at the Center for Biotechnology and Bioengineering, University of Pittsburgh and were used for experiments when they were 7 to 12 weeks old. All the animals were ear-tagged, randomized before experiments, and treated and examined in a blinded fashion. 1 × 10 5 of MCA205 tumor cells were injected i.d. into the flank(s) of experimental animals on day 0. Each group consisted of seven animals. In some experiments, mice received 1 × 10 9 p.f.u. of adenoviral vector or HBSS as a control on days 7 and 10. In other experiments using coadministration of adenoviral vector and DCs, mice received 3 × 10 8 p.f.u. of adenoviral vector or HBSS and 1 × 10 6 of DC. The tumor size was measured every 3-4 days and expressed as the product of the perpendicular diameters of individual tumors. On day 14, two animals in each group were killed to harvest samples to be tested in vitro. Each animal experiment was repeated at least twice and representative results are shown.
Flow cytometry
For phenotypic analysis, DCs were stained with PE-or FITC-conjugated monoclonal antibodies against murine cell surface molecules (CD11c, CD80, CD86, Gr-1, H-2Kb, I-Ab and appropriate isotype controls, all from PharMingen, San Diego, CA, USA). Lymphoid cells harvested from lymph nodes were stained with CD4 and CD8. They were examined by flow cytometry (FACScan, Becton Dickinson, Sunnyvale, CA, USA).
Evaluation of effector function: cytokine release, CTLs assays
Lymphoid cells were obtained from the groin lymph nodes harvested from mice which had received i.t. injection of adenoviral vector or HBSS, or adenoviral vector and DCs 7 days earlier. To examine the IFN-␥ response of the lymphoid cells, these cells (contaminating erythrocytes were lysed with 0.83 M NH4Cl buffer; 2 × 10 6 ) were cocultured with 2 × 10 5 irradiated (10 000 rad) MCA205 in the presence of rhIL-2 (25 IU/ml) in 24-well plates for 40 h. The resultant supernatant was collected and examined with an ELISA specific for mIFN-␥ (PharMingen). To obtain CTLs from these cells, 2 × 10 6 cells were restimulated in vitro with 2 × 10 5 irradiated (10 000 rad) MCA205 in the presence of rhIL-2 (25 IU/ml) for 5 days. Cytotoxic activity was examined using lymphoid cells after co-culture. Viable lymphoid cells were counted using trypan blue exclusion and used as effector cells in a standard 4 h 51 Cr release assay against target cells. In brief, 10 6 cells of each target were labeled with 100 Ci of Na2
51
CrO4 for 1 h, rinsed twice, and plated with target cells at an appropriate E:T ratio in 96-well round bottom plates. The supernatant (100 l) was collected after a 4-h incubation and the radioactivity was counted with a ␥-counter. Specific lysis was calculated using the following formula: % specific lysis = 100 × (experimental release Ϫ spontaneous release)/(maximal release Ϫ spontaneous release). Forty hours after the culture, 0.4 ml of supernatant was collected for ELISA analysis for IFN-␥ (Pharmingen). The lower detection limit of these assays was 15 pg/ml. For cytolytic assay, cells were cultured for 4 days and collected and tested for cytotoxic activity.
Statistical evaluation
Statistical analysis was performed using repeated measure ANOVA method when comparing the in vivo tumor growth and cytotoxic activity in individual groups. Unpaired two-tailed Student's t test was used to compare cytokine expression. Differences were considered significant when the P value was less than 0.05.
